Homocystinuria is a metabolic disorder associated with defects in genes encoding for methionine metabolism enzymes. Vascular and connective tissue manifestations such as deep venous thrombosis, ectopia lentis and skeletal alterations are the major clinical features.
Homocystinuria (MIM# 236200) is a rare metabolic disorder (1:344.000) mainly due to cystathione beta-synthase (CBS) deficiency which causes increased urinary homocysteine (Hcy) and methionine excretion [1] . Major clinical manifestations involve eyes, skeleton, central nervous and vascular systems. Ocular and skeletal manifestations are shared by both homocystinuria and Marfan syndrome (MFS) patients, while aortic dilatation and valve prolapse and regurgitation, have been reported only in Marfan patients.
Patients are diagnosed during infancy, mostly after the onset of ectopia lentis (EL) [1, 2] , or because of venous thrombosis in later age. The homotetramer CBS (EC 4.2.1.22; chr.21q22.3) (Fig. 1) , enzyme in the transulfuration pathway, converts the potentially toxic Hcy into cysteine [3] . A continuously updated CBS website (http://www.uchsc.edu/ sm/cbs/cbs data/cbsmain.htm) lists 140 mutations in 624 patient alleles [4] . Homocystinuria can also be due to mutations in 5-10, Methylenetetrahydrofolate reductase (MTHFR; MIM#236250) [5] , methionine synthase reductase (MTRR) [6] and methionine synthase (MTR) [7] genes.
We investigated 5 homocystinuric Italian patients and an echocardiographic study/examination was performed according to the guidelines of the American Society of Echocardiography [8] . Controls were selected among apparently healthy Italian subjects with no history of sudden death, without venous thrombosis, cardiovascular, skeletal or eyes Marfan or homocystinuric manifestations. Biochemical and genetic factors predisposing to thrombotic events were evaluated as previously reported [9] [10] [11] [12] . Genomic DNA mutation analysis of CBS gene (Table 1 ) was performed [13] .
Clinical characteristics and molecular data of the 5 patients (4 males and 1 female) are shown in Table 2 . In 3 cases (Pts #1,3,4) the diagnosis was made after the first thrombotic event, in the other 2 cases (Pts#1,5) upon detection of EL.
All values for biochemical and genetic factors turned out to be in a normal range except for the following: two individuals who were homozygous for MTHFR: c.677C N T(Pt#3) and c.1298A N G(Pt#1); 2 were heterozygous for: MTRc.2756A N G (Pt#5) and MTHFRc.1298A N G(Pt#4); only one was double heterozygote for MTRc.2756A N G and MTHFRc.677C N T (Pt#2).
We found 6 heterozygous missense mutations (p.Pro49-Leu, p.Arg125Gln, p.Ile278Thr, p.Ala157Pro, p.Gly307Ser, p.Arg336His); 1 in frame deletion (p.Ile429del), 1 mRNA splicing mutation that alters intron 12 splice donor site (c.1357 + 1G N A).
Patient #2 leads the novel c.469G N C nucleotide CBS substitution in exon 4 corresponding to the p.Ala157Pro change localized in a highly conserved region (catalytic domain) at the dimer interface of the tetrameric protein structure. We found c.469G N C mutation in 3 out of 300 controls, so by definition this mutation has to be considered as a polymorphism. Moreover, this substitution would induce a bend in the protein structure but its pathogenic role remains to be defined for the relatively high frequency in controls (1%).Alternatively, a second mutation could be present in the promoter region not investigated.
Patient #3 leads another mutation, carried by an Argentinean patient [14] , recently published on-line that consists in a deletion of three nucleotides (c.1286_1288delTCA) causing a deletion of amino acid Ile429, the mutation being positioned in a non conserved domain. This mutation, however, is not present in 50 South American [14] and 300 Italian controls (this report).
The other 6 mutations are already reported in the database as pathogenic mutations.
The parents of patient #5 underwent hcy dosage and CBS mutation analysis. The father carried mutation p.Ile278Thr and mildly increased hcy level (23 µmol/L; n.v. b 19) while the mother, presenting mutation p.Arg125Gln, had normal hcy levels (9.8 µmol/L; n.v. b 13), both in heterozygous state.
Eight polymorphisms, 5 novel and 3 already published in the CBS database, were found (Table 2 ).
In our patients we detected heart and skin manifestations never reported in homocystinuric patients such as mild heart valve prolapse and/or regurgitation, and striae distensae suggesting, for the first time, that these patients can develop cardiovascular manifestations.
MacLean et al. [15] suggested that clinical homocystinuric manifestations related to the connective tissue may be correlated to the decrease of CBS production causing both an increase of hcy levels and a decrease of cysteines. The decrease of cysteines may affect the qualitative and quantitative synthesis of connective tissue proteins causing EL and other connective tissue manifestations. This hypothesis is based on the association of connective tissue alterations with a group of missense mutations located in the CBS C-terminal region and affecting the domain interacting with S-adenosylmethionine (AdoMet), so an increase of AdoMet cannot further stimulate CBS production. Our 2 patients with a mutation in CBS regulatory domain, carried mild cardiovascular, skeletal and cutaneous stigmas, confirming the MacLean's hypothesis [15] . Overall, the presence of a mild connective tissue involvement, including heart valve alterations and striae distensae in all 5 patients, suggests that the connective tissue pathology in homocystinuria is relevant in relation to the cardiovascular manifestations which may become more severe with aging. Recently Hubmacher et al. [16] demonstrated that high Hcy levels in homocystinuric patients can modify fibrillin-1 via disulfide bonds by rendering protein domains significantly more susceptible to proteolytic degradation. This impairment could cause the clinical manifestations, overlapping with MFS, present in these patients. These results support our hypothesis on the pathological molecular mechanism underlying the association between c.677C N T homozygous MTHFR polymorphism, mild homocysteinemia and more severe aortic manifestations in Marfan syndrome [17] thus strengthening the link between increased Hcy and damage to connective tissue proteins rich in cysteines, as fibrillin 1.
Our data emphasizes the importance of extending the clinical investigation for connective tissue manifestations present in Marfan syndrome to homocystinuric patients. Moreover, the detection of cardiovascular manifestations suggests long term follow-ups for each patient.
